Kornimate/medical-research-clean huggingface dataset:
breath condensate study in patients with cystic fibrosis.

Conditions: Cystic Fibrosis

Summary: there is an urgent need for a noninvasive method to diagnose bronchial infections and exacerbations in patients with cystic fibrosis (cf). the current method to diagnosed infections involves either collecting a sputum sample or obtaining a bronchoalveolar lavage (bal). however, some patients cannot produce sputum. at the same time the decision of when a patient has an exacerbation continues to be very subjective. in this exploratory study, we propose a new, noninvasive method to diagnose bronchial infections and to evaluate possible markers of inflammation that can assist in a noninvasive way in the determination of exacerbations.

we hypothesize that it is possible to recover microbial products causing infections in exhaled breath condensate (ebc) samples as well as to measure markers of inflammation like interleukin (il)-8, leukotriene b4 (ltb4), interleukin il-6, interleukin il-1b, tumor necrosis factor alpha, as well as proteases like neutrophil elastase, matrix metalloproteinase 2 and 9 and antiproteases like secretory leukoprotease inhibitor (slpi), alpha one antitrypsin and tissue inhibitor of metalloproteinase-1 (timp-1). as a way to compare our findings to systemic inflammation we will also measure c-reactive protein in serum. 20 patients with cystic fibrosis who have chronic bronchial infection and 20 controls will be recruited. their exhaled breath condensate and sputum samples will be collected and analyzed for the presence of bacteria through traditional, molecular and nuclear acid amplification methods as well as pyrosequencing analysis. we will also measure the above markers of inflammation and follow the cf patients for the following year so we can continue to collect exhaled breath condensate when they have an exacerbation and are admitted to the hospital as well as after treatment for the exacerbation. we will correlate these markers with patient's clinical features including pulmonary function test, body max index, cf pathogens, and cf genotype. if our hypothesis turns out to be true it will open up a possibility for a new noninvasive diagnostic and follow up method that will benefit cystic fibrosis patients. 2. hypothesis \& specific aims: a. microbial products can be recovered from exhaled breath condensate. b. that these microbial products recovered from exhaled breath correlate with that recovered from sputum c. markers of inflammation can be recovered from exhale breath condensate.

Eligibility criteria:
inclusion criteria: any patient with cystic fibrosis (cf) in the age range 18-65 years who is known to be chronically infected in their respiratory tract will be eligible as cases. any other patient or healthy subject in the age range 18-65 years who is not infected with pseudomonas in their respiratory tract will be eligible as controls. exclusion criteria: any study subject, who cannot co-operate with the study, cannot co-ordinate breathing or cannot breathe through a mouthpiece.
hfs-guided renal ablation for improving outcome of renal denervation procedure

Conditions: Hypertension

Summary: to increase the number of responders using hfs-guided renal artery denervation (rdn) in patients with resistant and moderate resistant hypertension


Eligibility criteria:
inclusion criteria: * office-based systolic blood pressure of ≥140/90 mm hg and \<160/100 mm hg (moderate resistant hypertension) or ≥160/100 mm hg (severe resistant hypertension), despite treatment with 3 antihypertensive drugs (including a diuretic). * a glomerular filtration rate ≥45 ml/min/1⋅73 m2, with modification of diet using a renal disease formula. exclusion criteria: * secondary causes of hypertension * severe renal artery stenosis or dual renal arteries * congestive heart failure * left ventricular ejection fraction \<35% * previous renal artery stenting or angioplasty * type 1 diabetes mellitus

Keywords: renal denervation ablation
effectiveness of repeated amiodarone dosing regimen versus standard dosing regimen in atrial fibrillation patient with rapid ventricular response

Conditions: Atrial Fibrillation

Summary: the goal of this clinical trial is to compare in atrial fibrillation patient with rapid ventricular response. the main question it aims to answer are effectiveness of repeated amiodarone dosing regimen versus standard dosing regimen in atrial fibrillation patient with rapid ventricular response participants will receive amiodarone iv treatment with different regimen * repeated dosing regimen * standard dosing regimen


Eligibility criteria:
inclusion criteria: * age above 18 years old * atrial fibrillation with rapid ventricular response patient (ventricular rate \> 110) exclusion criteria: * baseline ekg corrected qt interval (qtc) \< 500 msec * history of pulmonary fibrosis * history of cirrhosis * cardiac index \<2.2 l/min/m2 or cardiogenic shock * unstable arrhythmia * receive amiodarone within 3 months prior to present illness * pregnancy * amiodarone or iodine allergy
a preliminary investigation of pre-frontal repetitive transcranial magnetic stimulation (rtms) for the treatment of cannabis use disorder

Conditions: Cannabis Use Disorder

Summary: this investigation will preliminarily determine if a course of high-frequency rtms applied to the left dorsolateral prefrontal cortex, will reduce behavioral craving, and fmri cue-reactivity in treatment-seeking cannabis use disordered participants.

the overarching goal of this proposal is to investigate if a course of excitatory dlpfc rtms results in reduced cannabis behavioral craving in treatment-seeking individuals with cud (aim1). additionally, the investigators seek to explore the mechanistic underpinnings of any observed effect, by collecting functional magnetic resonance imaging data during cannabis cue administration before and after the treatment course (aim 2). these aims will be addressed through a nine-week, double-blind, randomized, sham-controlled study in which 72 treatment-seeking cannabis use disordered participants (36/group) will be given 20 sessions of either active or sham excitatory rtms applied to the dlpfc. rtms will be delivered over five weeks (2 sessions each day, two days each week). rtms will be applied in conjunction with a validated three-session motivational enhancement therapy (met) behavioral intervention.

Eligibility criteria:
inclusion criteria: 1. participants must be able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments. 2. participants must be between the ages of 18 and 60. 3. participants must meet dsm-5 criteria for at least moderate cannabis use disorder, with use of at least 20 out of the last 28 days. 4. participants must express a desire to quit cannabis. 5. participants must have a positive uds for cannabis during their baseline visit (confirming they are regular users). exclusion criteria: 1. participants must not be pregnant or breastfeeding. 2. participants must not meet moderate or severe use disorder of any other substance with the exception of nicotine use disorder. 3. participants must not be on any medications that have central nervous system effects. 4. participants must not have a history of/or current psychotic disorder or bipolar disorder. 5. participants must not have any other axis i condition requiring current treatment and must have a hrsd24 ≤10 indicating no clinically relevant depressive symptoms. 6. participants must not have a history of dementia or other cognitive impairment. 7. participants must not have active suicidal ideation, or a suicide attempt within the past 90 days. 8. participants must not have any contraindications to receiving rtms (e.g. metal implanted above the head, history of seizure, any known brain lesion). 9. participants must not have any unstable general medical conditions.
microbiologic contamination of home non invasive ventilators

Conditions: Chronic Respiratory Failure; COPD; Obesity Hypoventilation Syndrome

Summary: home non-invasive ventilators are daily used by patients with chronic respiratory failure. there are frequently used with warming and humidifying systems. these systems need to be cared for and frequently washed by the patient. the aim of this study is to evaluate if the humidifying system of home ventilators are colonized by microbiological germs.

the use of non-invasive ventilators is common for treating respiratory failure. their care relies on the patients and their carers. no study has assessed the efficacy of such care with respect to the number of microbiological specimens that remain in the humidifier.

Eligibility criteria:
inclusion criteria: * patient established on home non invasive ventilation for more than 6 months * with a compliance \>4hours/day * who brought their ventilator for the assessment * diagnosed with copd or obesity hypoventilation syndrome (ohs) * who consent * with an age \> 18 years exclusion criteria: * age under 18 * ongoing exacerbation * not able to consent * pregnant or breastfeeding
effect of pre-injection of lidocaine on myoclonus induced by induction with etomidate in elderly patients during general anesthesia

Conditions: General Anesthesia

Summary: to evaluate the effect of pre-injection of lidocaine on myoclonus induced by induction with etomidate during general anesthesia in elderly patients


Eligibility criteria:
inclusion criteria: * 1. aged between 60 and 81 years 2. body mass index: 20 to 30 kg/m2 3. american society of anesthesiology (asa) physical status: ⅰ or ⅱ 4. signed informed consent form exclusion criteria: * 1. use of sedatives or opioids 2. history of central nervous system diseases, like epilepsy, shaking palsy, or chorea, etc 3. hyperthyroidism 4. serious diabetes 5. hyperkalemia 6. cardiac surgery 7. serious ventricular disease or atrioventricular block 8. liver or renal dysfunction 9. allergies to amide local anesthetics or fat emulsion
study of coagulation factor viia marzeptacog alfa (activated) in subjects with hemophilia a or b

Conditions: Hemophilia A With Inhibitor; Hemophilia B With Inhibitor

Summary: the purpose of the trial is to evaluate the safety and efficacy of marzaa for on-demand treatment and control of bleeding episodes in hemophilia a or b patients with inhibitors compared with their standard of care (soc).


Eligibility criteria:
inclusion criteria: * diagnosis of congenital hemophilia a or b with inhibitors * male or female, age 12 or older * history of frequent bleeding episodes * affirmation of informed consent with signature confirmation and assent for children between ages 12 to 17 before any study related activities exclusion criteria: * previous participation in a clinical trial evaluating a modified rfviia agent * received an investigational drug within 30 days or 5 half-lives or absence of clinical effect * known hypersensitivity to trial or related product * known positive antibody to fvii or fviia detected by central lab at screening * have a coagulation disorder other than hemophilia a or b * be immunosuppressed * significant contraindication to participate
a study on the effects of soy protein on blood lipids in men and women with mild to moderate hypercholesterolemia

Conditions: Hypercholesterolemia

Summary: the objectives of the trial are to determine whether a non-commercial soy protein product, consumed as part of a low-saturated fat diet, reduces low-density lipoprotein cholesterol (ldl-c) concentrations in men and women with mild to moderate hypercholesterolemia, and affects other aspects related biomarkers.


Eligibility criteria:
inclusion criteria: * male or female * 18-79 years of age * fasting ldl-cholesterol level borderline to high range taking no cholesterol lowering medications * otherwise judged to be in good health, willing to maintain a stable body weight and follow the tlc diet throughout the trial. exclusion criteria: * chd or chd risk equivalent * pregnancy * food allergy or sensitivity to soy or milk protein * certain muscle, liver, kidney, lung or gastrointestinal conditions and medications * poorly controlled hypertension * cancer treated within prior 2 years

Keywords: hypercholesterolemia cholesterol soy
infliximab biosimilar for intravenous drip infusion 100 mg "pfizer" drug use investigation (rheumatoid arthritis)

Conditions: Rheumatoid Arthritis

Summary: to collect information on the safety and effectiveness of infliximab bs for intravenous drip infusion 100 mg "pfizer" against rheumatoid arthritis under actual status of use.


Eligibility criteria:
inclusion criteria: * patients with rheumatoid arthritis who started treatment with this drug * patients who received this drug for the first time after the day of launch of this drug.

Keywords: rheumatoid arthritis infliximab biosimilar
amantadine in treating cognitive & motor impairments in adolescents and adults with cerebral palsy

Conditions: Cerebral Palsy

Summary: cerebral palsy (cp) is a common childhood-onset disability associated with motor and cognitive impairments, however most research is focused on motor outcomes. the aim of this study is to determine the effects of amantadine, a dopaminergic agonist, on cognitive function in adolescents and adults with cp.

cp is a heterogeneous condition due to injury to the developing brain. it is a condition that is often marked by both cognitive and motor disorders as well as increased prevalence of depression and anxiety. while most studies have focused on improving motor dysfunction, fewer have investigated cognitive impairments associated with cp. dedicating a study to research the pharmacotherapeutic effect of amantadine on cognitive function in adolescents and adults with cerebral palsy fills an important gap in development of a potential innovative treatment for cognitive deficits. the investigators hope to determine the effects of amantadine on cognitive function in adolescents and adults with cp. the investigators will also evaluate secondary goals of improving gross and fine motor skills and mood.

Eligibility criteria:
inclusion criteria: * diagnosed with cerebral palsy exclusion criteria: * currently pregnant * unstable seizure condition * currently taking methadone * currently taking other dopamine agonists * currently taking anti-psychotic medication * previously taken amantadine * diagnosed with chronic kidney disease (ckd)

Keywords: cerebral palsy amantadine cognitive function gross motor skills fine motor skills mood
randomized trial:the effect of liquid food on the intake of energy and protein in malignant hematologic patients

Conditions: Hematological Disease; Delayed Gastric Emptying; Malignant Disease

Summary: the study investigates the effect of liquid food on the intake of energy and protein compared to solid food. one group will receive dietary counselling in fulfilling their need for energy and protein from liquid food and the other group from solid food.

the study investigates the effect of liquid food on the intake of energy and protein compared to solid food. one group will receive dietary counselling in fulfilling their need for energy and protein from liquid food and the other group from solid food. both groups need to register their dietary intake in a period of 14 days and will be weighed three times during the intervention. at the end of the intervention they need to fill out a questionnaire.

Eligibility criteria:
inclusion criteria: * patients with leukemia, lymphoma or other malignant hematological disease * adults * be able to talk and understand danish * be able to eat both solid and liquid food exclusion criteria: * not able to cooperate * need for total tube or parenteral nutrition * need for dialysis

Keywords: liquid diet solid diet
the combination of immunotherapy and neoadjuvant chemoradiotherapy in mss locally advanced rectal cancer

Conditions: Locally Advanced Rectal Cancer

Summary: the study evaluates the addition of immunotherapy of pd-1 antibody in neoadjuvant chemoradiotherapy in microsatellite stable (mss) locally advanced rectal cancer (larc). a total of 50 mss larc patients will receive 2 cycles of pd-1 antibody, followed by capecitabine plus irinotecan radiosensitized neoadjuvant chemoradiotherapy, and another 3 cycles of pd-1 antibody, finally received the total mesorectal excision (tme) and 6 cycles of adjuvant chemotherapy of xelox. the tumor response grade, adverse effects and long-term prognosis will be analyzed.


Eligibility criteria:
inclusion criteria: 1. pathological confirmed adenocarcinoma 2. clinical stage t3-4 and/or n+ 3. the distance from anal verge less than 12 cm 4. without distance metastases 5. age 18-70 years old, female and male 6. kps \>=70 7. ugt1a1\*28 6/6 or 6/7 8. the msi status is mss or p-mmr 9. without previous anti-cancer therapy or immunotherapy 10. with good compliance 11. signed the inform consent exclusion criteria: 1. pregnancy or breast-feeding women 2. history of other malignancies within 5 years 3. serious medical illness, such as severe mental disorders, cardiac disease, uncontrolled infection, etc. 4. immunodeficiency disease or long-term using of immunosuppressive agents 5. baseline blood and biochemical indicators do not meet the following criteria: neutrophils≥1.5×10\^9/l, hb≥90g/l, plt≥100×10\^9/l, alt/ast ≤2.5 uln, cr≤ 1 uln 6. dpd deficiency 7. ugt1a1\*28 7/7 8. the msi status is msi-h or d-mmr 9. allergic to any component of the therapy
relationship of realize mysuccess usage to outcomes of bariatric surgery

Conditions: Bariatric Surgery; Obesity; Weight Loss

Summary: the goal of this observational study is to assess the efficacy of realize my success (rms),a website that allows patients and providers to maintain contact via the website. we will compare rms users on a number of different variables with the goal of identifying which variables are associated with optimal outcomes (larger weight losses) at one year (and potentially beyond). the study has two primary objectives. the first is to assess changes in body weight at postoperative year 1 in frequent v. infrequent rms users. we predict that frequent users will achieve significantly greater reductions in weight at 6 and 12 months (and beyond) than infrequent users. the second objective is to assess changes in body weight at postoperative year 1 in persons who use different features of the rms site. we hypothesize that persons who, on a regular basis, record their food intake, track their physical activity and make specific behavioral goals will experience significantly greater reductions in weight beginning 6 months after surgery as compared to those who do not use these features of the rms site.


Eligibility criteria:
inclusion criteria: * 18-65 years old * bmi between 40-70 kg/m2 (or 35-70 kg/m2 in the presence of co-morbidities) * have registered in the realize mysuccess systema and have logged into the system at least once postoperatively. exclusion criteria: * we will be receiving/analyzing a data set based on the inclusion criteria, therefore there is no set exclusion criteria for our research.
national treatment approach versus standardized treatment protocol to manage patients with cleft lip and palate: a cross sectional study

Conditions: Cleft Lip and Palate

Summary: the main objective of this study is to provide data about treatment protocols for clp patients in egypt, and compare it to the management protocol suggested by the acpa.

this is a cross-setional survey to gather data concerning the current cl/p situation in our country. the main objectives of this study are 1. to identify if the healthcare providers in egypt work in cleft centers or teams 2. to assess if the healthcare providers are aware of the interdisciplinary team-based treatment approach that should be followed for clp patients' management. 3. to provide data about the cleft lip and palate management protocols that are being followed in egypt. 4. evaluation of the current status of cleft care and experiences of the health care providers involved in the management of the clp in egypt including orthodontists, omfs, otolaryngologists, plastic surgeons, speech therapists, dentists, psychiatrists, psychologists, pediatricians, nurses and social workers. 5. identify the presence or absence of cleft centers in our country. 6. identify the presence or absence or organized healthcare services for the clp patients in terms of parents' awareness about the condition and its management, as well as the presence of medical referrals between the specialists. 7. reporting the patients/parents' experiences throughout their treatment journey. 8. highlight the obstacles that could be faced by the health care providers as well as the patients along the treatment journey.

Eligibility criteria:
inclusion criteria: * • a sample of clp patients of varying age groups: (neonate and infant (birth -2 years of age), primary dentition stage (2 to 6 years of age), permanent dentition stage) * clp patients' parents will be included to answer questions involving clp infants and adolescents * paediatric dentists * paediatricians * gp dentists * oral and maxillofacial surgeons * plastic surgeons * orthodontists * nurses * speech therapists * prosthodontists * psychiatrists * psychologists * social workers * otolaryngologists exclusion criteria: * patients who don't suffer from cleft lip and palate * other specialists who aren't involved in the clp team
biomarkers of metabolic syndrome and prediabetes

Conditions: Metabolic Syndrome; Diabetes; Prediabetes; Hypertension

Summary: the purpose of this study is to investigate the feasibility of using salivary biomarkers to screen for complications of metabolic syndrome including prediabetes.


Eligibility criteria:
inclusion criteria: * between the ages of 18 and 65 years * males and females will be included in this study * all ethnic backgrounds will be included in this study * acceptable health based on interview and medical history * ability to comply with requirements of the study * ability and willingness to provide signed informed consent exclusion criteria: * eating or drinking anything but water within 10 hours of sample collection * autoimmune disease * type 1 diabetes * pregnancy (\< 6 weeks postpartum) * history of sjorgren's syndrome * dental work within the last two weeks * ongoing or active parasitic, fungal, viral or bacterial infection

Keywords: salivary biomarker metabolic syndrome prediabetes diabetes hypertension
follow-up of a study examining sleep management in united states veterans

Conditions: Insomnia

Summary: the first part of the pilot study, as detailed in unique protocol id no. 27522, is a randomized clinical trial that compares the effects of a mind-body bridging program with a sleep hygiene program to improve sleep quality in patients suffering from sleep disturbances. in part ii of the study, the investigators will perform a six month follow-up on the same subjects.

in this follow-up, we ask subjects to answer the same questionnaires that they completed at the beginning of the study. in addition we will ask subjects to complete a survey reflecting their medical history over the past 6 months and a second survey establishing their behavioral patterns and whether they continued practicing techniques of the intervention they were assigned to.

Eligibility criteria:
inclusion criteria: * have participated in part i of this study exclusion criteria: * the patient presents with significant mental health issues, such as severe psychosis or major depression (as verified by the primary care provider) or the patient is under intensive mental health case management.

Keywords: sleep problems awareness training program mind body bridging